Tissue & cell · 2025
Empagliflozin as a potential therapy for PCOS: Restoring hormonal balance and ovarian function in a letrozole-induced rat model.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Habib Heba A, El-Daly Mahmoud, Asiri Yahya I, Alqahtani Saud, Awad Eman M, Abdel Hafez Sara Mn, Ahmed Al-Shaimaa F, Anter Aliaa F
Аннотация
BACKGROUND: Polycystic ovarian syndrome (PCOS) is a prevalent endocrine disorder that often leads to infertility. The characteristic hyperandrogenemia and elevated luteinizing hormone /follicle stimulating hormone ratio, resulting in ovulation failure, are the hallmarks of PCOS. Recent preclinical and clinical studies revealed the potential of empagliflozin (EMPA; a sodium-glucose cotransporter-2 inhibitor) to improve PCOS symptoms. However, the effects of EMPA on endocrine disturbances and ovarian cyst formation were not thoroughly investigated.
OBJECTIVES: The primary objective of this study was to explore the potential of EMPA as a treatment for PCOS.
METHODS: PCOS was induced by daily administration of letrozole (1 mg/kg for 21 days). The PCOS group was then divided into PCOS (untreated), PCOS+EMPA (10 mg/kg), and PCOS + metformin (300 mg/kg). All groups, except for the vehicle-treated group, continued to receive letrozole throughout the 21-day treatment period. Serum and ovaries were collected for various measurements at the end of the experiments.
RESULTS: The results of the study showed that induction of PCOS resulted in high testosterone levels, luteinizing hormone /follicle stimulating hormone ratio, and ovarian weights. Disturbed apoptosis and high transforming growth factor-β and inducible nitric oxide synthase expression were also evident in the PCOS group. EMPA treatment resulted in an ameliorative effect of these changes, comparable to metformin's effect.
CONCLUSION: Our results suggest that EMPA could be a promising treatment for PCOS in rats, with its protective effect potentially mediated through its ability to restore hormonal imbalance and to restore transforming growth factor-β and inducible nitric oxide synthase expression, providing reassurance to the audience about its efficacy.
OBJECTIVES: The primary objective of this study was to explore the potential of EMPA as a treatment for PCOS.
METHODS: PCOS was induced by daily administration of letrozole (1 mg/kg for 21 days). The PCOS group was then divided into PCOS (untreated), PCOS+EMPA (10 mg/kg), and PCOS + metformin (300 mg/kg). All groups, except for the vehicle-treated group, continued to receive letrozole throughout the 21-day treatment period. Serum and ovaries were collected for various measurements at the end of the experiments.
RESULTS: The results of the study showed that induction of PCOS resulted in high testosterone levels, luteinizing hormone /follicle stimulating hormone ratio, and ovarian weights. Disturbed apoptosis and high transforming growth factor-β and inducible nitric oxide synthase expression were also evident in the PCOS group. EMPA treatment resulted in an ameliorative effect of these changes, comparable to metformin's effect.
CONCLUSION: Our results suggest that EMPA could be a promising treatment for PCOS in rats, with its protective effect potentially mediated through its ability to restore hormonal imbalance and to restore transforming growth factor-β and inducible nitric oxide synthase expression, providing reassurance to the audience about its efficacy.